Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | DBH | P09172 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787035 | 0.85 | ESR1 (0.56) | ESR1ESR2HDAC6HDAC8ABHD6 | |
| SCHEMBL7423258 | 0.83 | ESR1 (0.57) | ESR1ESR2HDAC6HDAC8ABHD6 | |
| SCHEMBL4071348 | 0.79 | ESR1 (0.50) | ESR1ESR2HDAC6HDAC8ALDH1A1 | |
| SCHEMBL13676320 | 0.79 | HDAC6 (0.46) | ESR2HDAC6HDAC8KDM4EDBH | |
| SCHEMBL19919810 | 0.79 | KDM4E (0.55) | HDAC6KDM4EDBHGAARECQL | |
| SCHEMBL13676336 | 0.79 | KDM4E (0.45) | HDAC6HDAC8KDM4EDBHGAA | |
| SCHEMBL1366408 | 0.78 | ESR1 (0.52) | ESR1ESR2HDAC6HDAC8KDM4E | |
| SCHEMBL12387505 | 0.78 | ESR1 (0.52) | ESR1ESR2HDAC6HDAC8ABHD6 | |
| SCHEMBL9052486 | 0.78 | HDAC6 (0.59) | ESR1ESR2HDAC6HDAC8ABHD6 | |
| Hydrochloric Acid SCHEMBL2315162 | 0.77 | ESR1 (0.51) | ESR1ESR2HDAC6HDAC8ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725240-A4 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-03-25 | — | — | EP | disclosed |
| US-20070185090-A1 | Muscarinic acetylchoine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1725240-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005094834-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185090-A1 | Muscarinic acetylchoine receptor antagonists | CHRM3, CHRNG, CHRM2 | ESR1 2788/4885ESR2 1153/4885HDAC6 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.